'Thyroid Cancer' Isn't Enough Information: Working Up a Family History Before Ruling Out a GLP-1
A woman with obesity and a family history of 'thyroid cancer,' unspecified histology, needs a real workup — not a reflexive GLP-1 exclusion or a reflexive dismissal — before her boxed-warning eligibility can actually be determined.
Simone B., a 36-year-old occupational therapist, mentioned her father's thyroid cancer diagnosis almost in passing while filling out her new-patient intake form, in the same unremarkable tone she used for her childhood tonsillectomy a few lines above it. She has obesity, a BMI of 33, and had come in specifically hoping to start a GLP-1 receptor agonist after watching two coworkers do well on one — a straightforward request that turned out to hinge entirely on a family-history detail neither she nor, until today, any of her prior physicians had thought to ask more about.
Her father was diagnosed with 'thyroid cancer' roughly fifteen years ago, treated with a thyroidectomy, and has been well since — but Simone doesn't know, and has never been told, which type. That distinction matters more than it might seem: every drug in the GLP-1 receptor agonist class carries a boxed warning against use in patients with a personal or family history of medullary thyroid carcinoma or MEN2, based on thyroid C-cell tumors observed in rodent studies whose relevance to human risk remains genuinely unresolved in the literature, but medullary thyroid carcinoma itself accounts for only a small minority of all thyroid cancers — the American Thyroid Association puts it at 1 to 2% in the United States — while the overwhelming majority are papillary or follicular and carry no such warning at all. Simone's 'thyroid cancer' could mean either, and nobody in the room could say which without more information than a decade-old family recollection provides.
She offered, unprompted, to call her father that evening to ask — a real, concrete step neither physician had actually needed to request, and one that, if it produces an old pathology report rather than just his own recollection, would settle far more of today's uncertainty than any test ordered in clinic could on its own.
In clinic, a family history that needed more than a label
I would not start a GLP-1 receptor agonist today, and I wouldn't rule it out permanently either — I'd get the workup that actually answers the question first. Every drug in this class carries a boxed warning against use in patients with a personal or family history of medullary thyroid carcinoma or MEN2, based on C-cell tumors seen in rodent studies; the human relevance of that signal remains genuinely uncertain, but the warning is real and the label is unambiguous about who it excludes.
Her father's diagnosis was recorded simply as 'thyroid cancer' in family history she reported secondhand — not confirmed as medullary specifically, and the American Thyroid Association puts medullary carcinoma at just 1 to 2% of US thyroid cancers, with the overwhelming majority papillary or follicular, so treating this as a confirmed MEN2 exclusion on the word 'thyroid cancer' alone would be overcautious in a way that isn't actually grounded in what we know yet.
Agreed on getting the workup rather than guessing either direction, and I'd be specific about what actually answers it: a serum calcitonin level, and ideally confirmation of her father's actual pathology report if it can be obtained, since 'thyroid cancer' in a family member's chart, without the specific histology, genuinely isn't enough information to act on responsibly in either direction.
If calcitonin comes back elevated or her father's pathology confirms medullary carcinoma, RET proto-oncogene testing would be the next step to actually establish or exclude MEN2 — and I'd hold the GLP-1 question entirely until that full picture is in, rather than starting her today on the assumption the family history is probably nothing.
That's the right sequence, and I'd add one practical note for today's visit: she has real, uncontrolled obesity-related risk in front of her right now, so while we're waiting on results, I don't want the workup itself to become an indefinite delay. I'd set a concrete timeline — results back and a decision made within a few weeks — rather than let this drift.
Agreed: order serum calcitonin today, pursue her father's original pathology report if it can be located, and hold the GLP-1 decision until that information is in hand, with a concrete follow-up scheduled within a few weeks so the workup doesn't drift into an indefinite delay.
Not agreed: what to recommend if her father's actual histology can't be located despite real effort. The endocrinologist would lean toward proceeding with a GLP-1 agonist if her own calcitonin comes back normal, treating that as sufficient reassurance on its own; the pharmacologist would want RET testing considered even with a normal calcitonin, given real, if uncommon, reports of normal calcitonin in early or occult medullary disease. That specific threshold was left open, pending the calcitonin result itself.